Objectives: ROCnRAL ANRS-157 was a single-arm study designed to evaluate a switch to a maraviroc (300 mg twice a day) plus raltegravir (400 mg twice a day) regimen in virologically suppressed HIV-1-infected patients (ClinicalTrials.gov: NCT01420523). The aim of this work was to investigate the factors associated with virological failure (VF) (5/44 patients) or virological rebound defined as one viral load (VL) .50 copies/mL or VL .1 copy/mL.
Introduction
During lifelong therapy, alternatives to NRTI and PI strategies are needed, particularly in patients with lipodystrophy syndrome. In the context of ART toxicity, particularly NRTIs and PIs associated with long-term toxicity, a dual combination of maraviroc/raltegravir was evaluated. The ROCnRAL ANRS-157 study was a pilot Phase II, single-arm, multicentre clinical trial designed to evaluate the capacity of the maraviroc plus raltegravir combination to maintain HIV viraemia ,50 copies/mL over 24 weeks in HIV-1-infected patients with controlled plasma viral load (pVL) under ART and clinical lipohypertrophy (ClinicalTrials.gov: NCT01420523). Maraviroc and raltegravir failed to maintain virological suppression in this population of HIV-1-infected patients. The viral rebound in five patients on the maraviroc/raltegravir regimen, suggesting a lack of virological robustness, led to premature discontinuation of the study in these long-term antiretroviral-experienced patients despite a benefit in lipid profile. 1 The aim of this study was to investigate the factors associated with virological failure (VF) or rebound in the clinical trial ROCnRAL ANRS-157.
Patients and methods
The study population consisted of HIV-1-infected adults with clinical lipohypertrophy enrolled and followed as previously described. 1 VF was defined as two consecutive measurements of HIV-1 RNA viral load (VL) .50 copies/mL, taken 2-4 weeks apart, or any treatment modification or discontinuation. Patients with a single value of HIV-1 RNA VL .50 copies/mL and a missing second HIV-1 RNA VL value and patients with two or more consecutive missing HIV RNA VL values were considered as failures. VF occurred in five patients in the trial.
Viral tropism was determined using the Geno2pheno algorithm [false positive rate (FPR) 20%] on blood cellular DNA. A more conservative FPR (20%) was chosen rather than the usual 10% recommended by the Agence Nationale de Recherches sur le Sida et les hé patites virales (ANRS) to increase the chances of detecting sequences of X4-tropic viruses. The integrase sequence was determined using Sanger sequencing. Genotypic resistance testing was performed on DNA at baseline and RNA in case of virological failure. The resistance mutations were interpreted with the latest ANRS genotypic algorithm (http://www. hivfrenchresistance.org).
Quantification of pVL was performed using the Amplicor monitor assay (Cobas 2.0, Roche Diagnostics, Basel, Switzerland), which has a lower detection limit of 20 HIV-1 RNA copies/mL. Below this cut-off, the assay indicates the qualitative detection of HIV-1 RNA VL in the range of 1 -20 copies/mL.
Whole blood was collected at baseline (BL) and cell-associated DNA in PBMCs was quantified as previously described. 2 The 454 sequencing technology (454 Life Sciences; Roche Diagnostics Corp., Branford, CT, USA), based on ultradeep sequencing (UDS), was used to study integrase resistance and viral tropism. HIV DNA was extracted from 400 mL of each available sample with the QIAamp DNA blood kit (Qiagen GmbH, Hilden, Germany), according to the manufacturer's instructions. Fragments of 334 and 573 bp were PCR amplified with primers as previously described for gp120 and integrase genes, respectively. 3, 4 The protocol was previously described. 5 The data generated with the UDS method were first analysed with PyroClass. Then, tropism was determined by Geno2pheno [454] . A patient was considered to have X4-tropic variants when the percentage of X4-tropic viruses was .2%. 6 The integrase mutations were searched with PyroMut according to the latest ANRS mutation list (http://www.hivfrenchresistance.org/) and IAS-USA list (https://www.iasusa.org/content/essential-managementhiv-infection).
Statistical analyses were performed with IBM SPSS version 22.0 for Windows. Univariate and multivariable Cox proportional hazards models were used to identify factors predictive of virological rebound at .50 copies/mL in patients with pVL ,50 copies/mL at baseline and at .1 copy/mL in those with pVL ,1 copy/mL at baseline, among the following variables: age, sex, ethnicity, CDC stage, transmission group, previous ART, duration of ART, BL CD4 cell count, BL CD8 cell count, CD4/CD8 ratio, nadir CD4 cell count, time since HIV diagnosis, plasma VL zenith, BL plasma HIV RNA VL, duration of suppressed viraemia, BL HIV DNA in PBMCs, HIV-1 subtype, tropism UDS, FPR tropism and presence of integrase mutations. 1 All variables providing a P value ,0.15 in the univariate analysis were retained for the multivariable analysis. The McNemar test was used to compare changes in categorical variables between baseline and study timepoints (weeks 4, 8, 12, 16, 20 and 24 and end of the study).
Results
All included patients in the ROCnRAL ANRS-157 trial had R5-tropic viruses determined by genotypic algorithm Geno2pheno 20% and WT viruses for the integrase gene determined by Sanger sequencing in DNA. Overall, the success rate over 24 weeks was 79% (95% CI 62% -89%, Kaplan -Meier estimate). Between weeks 8 and 20, two patients developed adverse events and five patients experienced VF (two consecutive VLs of .50 copies/mL). 1 From these five patients in VF, viruses analysed by Sanger sequencing showed no resistance mutations in the integrase gene for two of them, while plasma concentrations of maraviroc and/or raltegravir suggested poor compliance to therapy. The three remaining patients had Y143C-and CXCR4-using virus, N155H-and CXCR4-using virus and F121Y (Table 1 ). 1 The HIV-1 strains with Y143C and N155H remained susceptible to dolutegravir while the HIV-1 with F121Y was resistant to all integrase inhibitors.
To better understand the reasons for the strategy failure and the potential implications of minority variants in the ROCnRAL ANRS-157 trial, HIV-1 tropism and integrase gene resistance were evaluated at baseline by UDS in DNA. Among the 44 patients, 3 had .2% of X4-tropic viruses (3.5%, 3.1% and 7.3%). One of them presented VF with R5-tropic viruses at week 8 ( Table 1) . Some minority variants with resistance-associated mutations in the integrase gene were detected in three patients (E138K 4.3%; G140S 2.6%; E138K 1.0%). However, none of them experienced VF. Importantly, we did not detect by UDS at baseline any of the resistance-associated mutations (N155H, Y143C and F121Y) that were selected afterwards at the time of virological failure.
To explore the hypothesis of a lack of robustness of the maraviroc/raltegravir combination, all plasma samples were evaluated using the ultrasensitive VL. The proportion of patients with VL ,1 copy/mL did not significantly change over time (P .0.25 between BL and study timepoints, McNemar test): 72%, 63%, 72%, 68%, 57%, 47%, 68% and 69% at BL, week 4, week 8, week 12, week 16, week 20, week 24 and end of the study, respectively. Median BL cell-associated DNA in PBMCs was similar in patients with BL pVL ,1 and .1 copy/mL (2.77 and 2.96 log 10 copies/10 6 PBMCs, P ¼ 0.384).
In addition to the five patients with VF, seven experienced a viral blip (pVL .50 copies/mL followed by a second HIV RNA value ,50 copies/mL). None of the studied factors was found to be associated with virological rebound at .50 copies/mL ( Table 2) .
The factors potentially associated with a virological rebound at .1 copy/mL were evaluated among the 31 patients with a BL VL ,1 copy/mL. During the follow-up, 12/31 patients constantly had VL ,1 copy/mL while 19 patients experienced at least a VL .1 copy/mL. Table 3 shows the results of univariate and multivariable analysis of factors potentially predictive of virological rebound .1 copy/mL. Three factors were retained for the multivariable analysis: HIV DNA in PBMCs (P ¼ 0.065), age (P ¼ 0.065) and transmission group (P ¼ 0.130). However, none of them was found to be an independent predictive factor of rebound .1 copy/mL.
Discussion
In a maraviroc/raltegravir treatment as a switch strategy, in case of virological failure, there is a risk of emergence of X4-tropic viruses and integrase resistance mutations. UDS in DNA was able to detect some minority X4-tropic variants or integrase resistance mutations at baseline. However, these minority variants in DNA did not emerge at failure and did not explain the VF. No factor was found to be predictive of viral rebound .50 copies/mL or .1 copy/mL, probably owing to a lack of Soulié et al.
statistical power. Indeed, only 44 patients out of 90 initially planned were enrolled due to the premature discontinuation of the study.
At the time of virological failure, three of the five failing patients had HIV-1 viruses with integrase resistance mutations with the emergence of X4-tropic viruses in two of them. The Y143C and N155H mutations conferred resistance to raltegravir and elvitegravir while F121Y resulted in resistance to the whole integrase inhibitor class. 7 Furthermore, two patients had low plasma concentrations of maraviroc and/or raltegravir, presumably having adherence problems or intestinal malabsorption, and presented neither integrase mutations nor X4-tropic viruses. A potential explanation for lack of adherence was the switch from a once-daily regimen to a twicedaily one. However, in this set of patients only one had previously had twice-daily treatment, and presented raltegravir and maraviroc plasma C min 12 h target values (.50 ng/mL). 8 Genotypic determination of HIV tropism was performed with cell-derived viral DNA using Sanger and UDS techniques, as it has been suggested that tropism predictions based on UDS could improve therapeutic management. 6, 9 The presence of three patients with minority X4-tropic variants was evidenced by UDS and did not seem to be associated with the occurrence of VF. As previously mentioned, the PBMC compartment could appear as a suboptimal predictor of HIV tropism compared with plasma despite promising potential for the DNA-based tropism method. 10 Nevertheless, in the context of switch strategies, DNA testing may be the only option. Similarly, UDS allowed the detection of some integrase minority resistant variants and was not found to be a factor predictive of virological rebound. This raises the question of the potential presence of minority variants in compartments other than PBMCs.
As residual viraemia could impact inflammatory markers and carotid intima-media thickness, ultrasensitive VL was explored. The proportion of patients with ultrasensitive VL was constant over time and BL cell-associated DNA in PBMCs was similar in the groups of patients with ultrasensitive pVL .1 or ,1 copy/mL. 11, 12 Thus, in this context, low VL did not explain the VF.
Furthermore, we recently demonstrated the absence of deleterious drug -drug interaction between maraviroc and raltegravir in this study population. 13 Overall, taking into consideration all virological and pharmacological data, we have not been able to identify reasons for treatment failure in 5 out of 44 patients with the dual maraviroc/raltegravir combination.
Some limitations of our study could be mentioned: low number of patients; interpretation of UDS results according to clinical observation; and analysis performed on whole blood, which may not be sensitive compared with selection of quiescent CD4 cell count as the main HIV cellular reservoir.
In conclusion, the ROCnRAL ANRS-157 study suggests that, in a population of long-term-treated ageing patients, maraviroc/raltegravir dual therapy lacks virological robustness, resulting in the emergence of resistance mutations, and therefore cannot be recommended for further evaluation on a larger scale. As no virological or pharmacological factors were found to be associated with VF, this could argue in favour of a lack of potency of this combination. However, the results of a Phase II pilot study of simplification to maraviroc/raltegravir dual therapy after 6 months of maraviroc/raltegravir/tenofovir/emtricitabine quadruple therapy in ART-naive HIV-1-infected patients with CCR5tropic virus (NCT01291459) are expected and it will be interesting to know the efficacy of this dual therapy in a different population Raltegravir/maraviroc therapy in HIV-infected lipohypertrophic patients 3343 JAC of patients. Finally, these results do not preclude the use of maraviroc in combination with other antiretrovirals with a higher genetic barrier.
